Published in Mol Cell on September 10, 2004
Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer (2009) 9.33
Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev (2011) 5.02
Cell apoptosis: requirement of H2AX in DNA ladder formation, but not for the activation of caspase-3. Mol Cell (2006) 3.62
Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci U S A (2006) 3.33
Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance. Proc Natl Acad Sci U S A (2006) 3.02
Differential effects of JNK1 and JNK2 inhibition on murine steatohepatitis and insulin resistance. Hepatology (2009) 2.78
Tumor necrosis factor-induced toxic liver injury results from JNK2-dependent activation of caspase-8 and the mitochondrial death pathway. J Biol Chem (2006) 2.36
The miR-17-5p microRNA is a key regulator of the G1/S phase cell cycle transition. Genome Biol (2008) 2.29
Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J Clin Invest (2008) 2.26
A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. Gastroenterology (2012) 2.15
The kinase Jnk2 promotes stress-induced mitophagy by targeting the small mitochondrial form of the tumor suppressor ARF for degradation. Nat Immunol (2015) 2.06
c-Jun N-terminal kinase modulates oxidant stress and peroxynitrite formation independent of inducible nitric oxide synthase in acetaminophen hepatotoxicity. Toxicol Appl Pharmacol (2010) 1.84
JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. J Biol Chem (2009) 1.82
Critical role of c-jun (NH2) terminal kinase in paracetamol- induced acute liver failure. Gut (2006) 1.82
PUMA-mediated apoptosis drives chemical hepatocarcinogenesis in mice. Hepatology (2011) 1.82
The functional contrariety of JNK. Mol Carcinog (2007) 1.77
Emerging roles of ATF2 and the dynamic AP1 network in cancer. Nat Rev Cancer (2010) 1.76
JNK signalling modulates intestinal homeostasis and tumourigenesis in mice. EMBO J (2009) 1.74
Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition. Gastroenterology (2009) 1.73
c-Jun N-terminal kinase 2 (JNK2) antagonizes the signaling of differentiation by JNK1 in human myeloid leukemia cells resistant to vitamin D. Leuk Res (2009) 1.64
Single and combined silencing of ERK1 and ERK2 reveals their positive contribution to growth signaling depending on their expression levels. Mol Cell Biol (2007) 1.62
JNK1 phosphorylation of Cdt1 inhibits recruitment of HBO1 histone acetylase and blocks replication licensing in response to stress. Mol Cell (2011) 1.61
FoxM1 regulates transcription of JNK1 to promote the G1/S transition and tumor cell invasiveness. J Biol Chem (2008) 1.58
Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease. Prog Lipid Res (2012) 1.51
IKKbeta programs to turn on the GADD45alpha-MKK4-JNK apoptotic cascade specifically via p50 NF-kappaB in arsenite response. J Cell Biol (2006) 1.46
CARMA1-mediated NF-kappaB and JNK activation in lymphocytes. Immunol Rev (2009) 1.44
c-Jun NH2-terminal kinase 1 plays a critical role in intestinal homeostasis and tumor suppression. Am J Pathol (2007) 1.44
Amniotic Membrane Modifies the Genetic Program Induced by TGFß, Stimulating Keratinocyte Proliferation and Migration in Chronic Wounds. PLoS One (2015) 1.44
The CARMA1-Bcl10 signaling complex selectively regulates JNK2 kinase in the T cell receptor-signaling pathway. Immunity (2006) 1.40
MicroRNAs MiR-17, MiR-20a, and MiR-106b act in concert to modulate E2F activity on cell cycle arrest during neuronal lineage differentiation of USSC. PLoS One (2011) 1.40
Phosphorylation by c-Jun NH2-terminal kinase 1 regulates the stability of transcription factor Sp1 during mitosis. Mol Biol Cell (2008) 1.31
Expression pattern, regulation, and functions of methionine adenosyltransferase 2beta splicing variants in hepatoma cells. Gastroenterology (2007) 1.30
Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces osteosarcoma cell invasion. J Biol Chem (2008) 1.29
The anti-death machinery in IKK/NF-kappaB signaling. J Clin Immunol (2005) 1.27
Ethanol-induced HO-1 and NQO1 are differentially regulated by HIF-1alpha and Nrf2 to attenuate inflammatory cytokine expression. J Biol Chem (2010) 1.27
Core erythropoietin receptor signals for late erythroblast development. Blood (2005) 1.26
Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer. J Hepatol (2008) 1.25
AIMP2/p38, the scaffold for the multi-tRNA synthetase complex, responds to genotoxic stresses via p53. Proc Natl Acad Sci U S A (2008) 1.23
MAPK signaling in inflammation-associated cancer development. Protein Cell (2010) 1.23
c-Jun controls histone modifications, NF-kappaB recruitment, and RNA polymerase II function to activate the ccl2 gene. Mol Cell Biol (2008) 1.20
TBP is differentially regulated by c-Jun N-terminal kinase 1 (JNK1) and JNK2 through Elk-1, controlling c-Jun expression and cell proliferation. Mol Cell Biol (2006) 1.16
JNK-mediated phosphorylation of Cdc25C regulates cell cycle entry and G(2)/M DNA damage checkpoint. J Biol Chem (2010) 1.14
MEKK1 mediates the ubiquitination and degradation of c-Jun in response to osmotic stress. Mol Cell Biol (2006) 1.12
C-Jun NH2 terminal kinase (JNK) is an essential mediator of Toll-like receptor 2-induced corneal inflammation. J Leukoc Biol (2008) 1.11
Tumor necrosis factor receptor 1/c-Jun-NH2-kinase signaling promotes human neoplasia. Cancer Res (2007) 1.11
JNK signalling in cancer: in need of new, smarter therapeutic targets. Br J Pharmacol (2014) 1.11
JNK regulation of hepatic manifestations of the metabolic syndrome. Trends Endocrinol Metab (2010) 1.10
Mechanisms and clinical implications of hepatocyte lipoapoptosis. Clin Lipidol (2010) 1.07
Molecular mechanisms of liver injury and hepatocarcinogenesis: focusing on the role of stress-activated MAPK. Patholog Res Int (2012) 1.04
Inflammation- and stress-related signaling pathways in hepatocarcinogenesis. World J Gastroenterol (2012) 1.04
Differential roles of JNK in ConA/GalN and ConA-induced liver injury in mice. Am J Pathol (2008) 1.03
JNK2 is activated during ER stress and promotes cell survival. Cell Death Dis (2012) 1.02
The JNKs differentially regulate RNA polymerase III transcription by coordinately modulating the expression of all TFIIIB subunits. Proc Natl Acad Sci U S A (2009) 1.02
c-Jun N-terminal kinase inhibitor SP600125 modulates the period of mammalian circadian rhythms. Neuroscience (2007) 1.01
Developing tTA transgenic rats for inducible and reversible gene expression. Int J Biol Sci (2009) 1.00
The mitogen-activated protein kinase kinase 4 has a pro-oncogenic role in skin cancer. Cancer Res (2010) 0.99
JNK1 is not essential for TNF-mediated joint disease. Arthritis Res Ther (2004) 0.99
c-Jun N-Terminal Kinases Mediate a Wide Range of Targets in the Metastatic Cascade. Genes Cancer (2013) 0.98
CARMA1 controls Th2 cell-specific cytokine expression through regulating JunB and GATA3 transcription factors. J Immunol (2012) 0.97
c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer. Clin Cancer Res (2009) 0.97
c-Jun NH2-terminal kinase is required for lineage-specific differentiation but not stem cell self-renewal. Mol Cell Biol (2010) 0.97
Phosphorylation of Bad at Thr-201 by JNK1 promotes glycolysis through activation of phosphofructokinase-1. J Biol Chem (2008) 0.96
The miR-17 family links p63 protein to MAPK signaling to promote the onset of human keratinocyte differentiation. PLoS One (2012) 0.95
Proteinase-activated receptor-1 and -2 induce the release of chemokine GRO/CINC-1 from rat astrocytes via differential activation of JNK isoforms, evoking multiple protective pathways in brain. Biochem J (2007) 0.95
DNA topoisomerase I is a cofactor for c-Jun in the regulation of epidermal growth factor receptor expression and cancer cell proliferation. Mol Cell Biol (2005) 0.95
Kinetic analysis of synovial signalling and gene expression in animal models of arthritis. Ann Rheum Dis (2009) 0.94
Basal cancer cell survival involves JNK2 suppression of a novel JNK1/c-Jun/Bcl-3 apoptotic network. PLoS One (2009) 0.94
Induction of apoptosis in human leukemia cells by grape seed extract occurs via activation of c-Jun NH2-terminal kinase. Clin Cancer Res (2009) 0.93
Inhibition of PDE4B suppresses inflammation by increasing expression of the deubiquitinase CYLD. Nat Commun (2013) 0.93
JAMP, a Jun N-terminal kinase 1 (JNK1)-associated membrane protein, regulates duration of JNK activity. Mol Cell Biol (2005) 0.92
c-Jun N-terminal kinase 1 is required for Toll-like receptor 1 gene expression in macrophages. Infect Immun (2007) 0.92
ADAP regulates cell cycle progression of T cells via control of cyclin E and Cdk2 expression through two distinct CARMA1-dependent signaling pathways. Mol Cell Biol (2012) 0.91
Hypoxia induces unique proliferative response in adventitial fibroblasts by activating PDGFβ receptor-JNK1 signalling. Cardiovasc Res (2012) 0.91
JNK is a novel regulator of intercellular adhesion. Tissue Barriers (2013) 0.90
Miz1 is a signal- and pathway-specific modulator or regulator (SMOR) that suppresses TNF-alpha-induced JNK1 activation. Proc Natl Acad Sci U S A (2009) 0.90
Jun-regulated genes promote interaction of diffuse large B-cell lymphoma with the microenvironment. Blood (2014) 0.90
Therapeutic implications of targeting the PI3Kinase/AKT/mTOR signaling module in melanoma therapy. Am J Cancer Res (2012) 0.90
Growth factor stimulation induces cell survival by c-Jun. ATF2-dependent activation of Bcl-XL. J Biol Chem (2010) 0.89
Requirements for PKC-augmented JNK activation by MKK4/7. Int J Biochem Cell Biol (2007) 0.88
PRAK suppresses oncogenic ras-induced hematopoietic cancer development by antagonizing the JNK pathway. Mol Cancer Res (2012) 0.88
Regulation of expression of matrix metalloproteinase-9 by JNK in Raw 264.7 cells: presence of inhibitory factor(s) suppressing MMP-9 induction in serum and conditioned media. Exp Mol Med (2009) 0.87
The requirement of c-Jun N-terminal kinase 2 in regulation of hypoxia-inducing factor-1α mRNA stability. J Biol Chem (2012) 0.86
PI3K/Akt/JNK/c-Jun signaling pathway is a mediator for arsenite-induced cyclin D1 expression and cell growth in human bronchial epithelial cells. Curr Cancer Drug Targets (2009) 0.86
Inactivation of JNK1 enhances innate IL-10 production and dampens autoimmune inflammation in the brain. Proc Natl Acad Sci U S A (2006) 0.86
TLRs, NF-κB, JNK, and Liver Regeneration. Gastroenterol Res Pract (2010) 0.86
Enzyme kinetics and interaction studies for human JNK1β1 and substrates activating transcription factor 2 (ATF2) and c-Jun N-terminal kinase (c-Jun). J Biol Chem (2012) 0.85
Stimulation of macrophage TNFalpha production by orthopaedic wear particles requires activation of the ERK1/2/Egr-1 and NF-kappaB pathways but is independent of p38 and JNK. J Cell Physiol (2008) 0.85
Targeting RTK Signaling Pathways in Cancer. Cancers (Basel) (2015) 0.85
COOH-terminal Src kinase-mediated c-Jun phosphorylation promotes c-Jun degradation and inhibits cell transformation. Cancer Res (2006) 0.85
JunD protects the liver from ischemia/reperfusion injury by dampening AP-1 transcriptional activation. J Biol Chem (2008) 0.85
The oncogenic transcription factor c-Jun regulates glutaminase expression and sensitizes cells to glutaminase-targeted therapy. Nat Commun (2016) 0.84
Investigating the role of c-Jun N-terminal kinases in the proliferation of Werner syndrome fibroblasts using diaminopyridine inhibitors. Chem Cent J (2011) 0.83
Hepatotoxicity mediated by pyrazole (cytochrome P450 2E1) plus tumor necrosis factor alpha treatment occurs in c-Jun N-terminal kinase 2-/- but not in c-Jun N-terminal kinase 1-/- mice. Hepatology (2011) 0.82
Hepatic apoptosis postburn is mediated by c-Jun N-terminal kinase 2. Shock (2013) 0.82
Delivery strategies and potential targets for siRNA in major cancer types. Adv Drug Deliv Rev (2016) 0.82
JNK Signaling: Regulation and Functions Based on Complex Protein-Protein Partnerships. Microbiol Mol Biol Rev (2016) 0.81
New benzimidazole acridine derivative induces human colon cancer cell apoptosis in vitro via the ROS-JNK signaling pathway. Acta Pharmacol Sin (2015) 0.81
Role of host-encoded proteins in restriction of retroviral integration. Front Microbiol (2012) 0.81
JNKing Revealed. Mol Cell (2004) 0.81
Immunity, inflammation, and cancer. Cell (2010) 28.27
In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature (2007) 28.24
Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. Cell Stem Cell (2007) 21.58
Missing pieces in the NF-kappaB puzzle. Cell (2002) 17.83
A central role for JNK in obesity and insulin resistance. Nature (2002) 17.27
Disease-specific induced pluripotent stem cells. Cell (2008) 16.95
IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell (2004) 15.82
Induced pluripotent stem cells generated without viral integration. Science (2008) 13.38
Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science (2007) 12.91
Defining molecular cornerstones during fibroblast to iPS cell reprogramming in mouse. Cell Stem Cell (2008) 12.45
IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med (2005) 12.07
Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol (2009) 11.76
IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell (2009) 11.52
The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol (2004) 10.85
AP-1 as a regulator of cell life and death. Nat Cell Biol (2002) 10.10
Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat Biotechnol (2010) 9.24
Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell (2005) 9.16
Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell (2002) 9.10
Regulation and function of IKK and IKK-related kinases. Sci STKE (2006) 8.98
AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer (2003) 8.88
IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell (2005) 8.78
A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest (2007) 8.54
Intracellular pattern recognition receptors in the host response. Nature (2006) 8.04
Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell (2010) 8.04
Targeted bisulfite sequencing reveals changes in DNA methylation associated with nuclear reprogramming. Nat Biotechnol (2009) 7.59
Guidelines and techniques for the generation of induced pluripotent stem cells. Cell Stem Cell (2008) 7.57
Reaching a genetic and molecular understanding of skeletal development. Dev Cell (2002) 7.55
Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science (2006) 7.35
Aberrant silencing of imprinted genes on chromosome 12qF1 in mouse induced pluripotent stem cells. Nature (2010) 7.05
p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell (2008) 6.88
Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature (2009) 6.85
Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity. Cell (2008) 6.83
Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature (2009) 6.67
Efficient method to generate single-copy transgenic mice by site-specific integration in embryonic stem cells. Genesis (2006) 6.64
Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov (2009) 6.36
Inflammation and colon cancer. Gastroenterology (2010) 6.32
Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol (2011) 6.17
NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature (2008) 6.13
A high-efficiency system for the generation and study of human induced pluripotent stem cells. Cell Stem Cell (2008) 5.99
Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature (2005) 5.72
Induced pluripotent stem cell generation using a single lentiviral stem cell cassette. Stem Cells (2009) 5.69
Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med (2011) 5.66
The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity (2002) 5.38
JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity. Cell Metab (2007) 5.38
Oct4 expression is not required for mouse somatic stem cell self-renewal. Cell Stem Cell (2007) 5.29
Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing. Science (2005) 5.25
The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell (2006) 5.18
Induced pluripotency: history, mechanisms, and applications. Genes Dev (2010) 4.89
A validated regulatory network for Th17 cell specification. Cell (2012) 4.82
Incomplete DNA methylation underlies a transcriptional memory of somatic cells in human iPS cells. Nat Cell Biol (2011) 4.77
NF-κB and the link between inflammation and cancer. Immunol Rev (2012) 4.74
Epithelial-cell-intrinsic IKK-beta expression regulates intestinal immune homeostasis. Nature (2007) 4.68
Reprogramming of neural progenitor cells into induced pluripotent stem cells in the absence of exogenous Sox2 expression. Stem Cells (2008) 4.67
NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev (2008) 4.61
Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature (2011) 4.57
NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell (2007) 4.56
Correction of a genetic defect by nuclear transplantation and combined cell and gene therapy. Cell (2002) 4.56
RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature (2002) 4.44
Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature (2012) 4.41
Analysis of histone 2B-GFP retention reveals slowly cycling hematopoietic stem cells. Nat Biotechnol (2008) 4.41
A molecular roadmap of reprogramming somatic cells into iPS cells. Cell (2012) 4.41
Reprogramming of pancreatic beta cells into induced pluripotent stem cells. Curr Biol (2008) 4.34
Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol (2008) 4.33
IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature (2005) 4.31
An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell (2011) 4.29
Sox2(+) adult stem and progenitor cells are important for tissue regeneration and survival of mice. Cell Stem Cell (2011) 4.29
Differentiation stage determines potential of hematopoietic cells for reprogramming into induced pluripotent stem cells. Nat Genet (2009) 4.28
JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. Cell (2004) 4.28
Macrophage apoptosis by anthrax lethal factor through p38 MAP kinase inhibition. Science (2002) 4.26
NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Res (2010) 4.10
Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev (2009) 4.10
IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy. J Clin Invest (2005) 4.07
Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature (2007) 4.00
Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell (2004) 3.98
Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell (2003) 3.92
The molecular clock mediates leptin-regulated bone formation. Cell (2005) 3.88
Sestrin as a feedback inhibitor of TOR that prevents age-related pathologies. Science (2010) 3.86
The two faces of IKK and NF-kappaB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat Med (2003) 3.85
A KH domain RNA binding protein, KSRP, promotes ARE-directed mRNA turnover by recruiting the degradation machinery. Mol Cell (2004) 3.71
Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med (2005) 3.70
The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med (2008) 3.68
Jun turnover is controlled through JNK-dependent phosphorylation of the E3 ligase Itch. Science (2004) 3.66
Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell (2008) 3.58
Redundant pathways for negative feedback regulation of bile acid production. Dev Cell (2002) 3.51
The HECT family of E3 ubiquitin ligases: multiple players in cancer development. Cancer Cell (2008) 3.35
Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci U S A (2006) 3.33
The AP-1 transcription factor c-Jun is required for efficient axonal regeneration. Neuron (2004) 3.33
Activation of IKKalpha target genes depends on recognition of specific kappaB binding sites by RelB:p52 dimers. EMBO J (2004) 3.32
A NOD2-NALP1 complex mediates caspase-1-dependent IL-1beta secretion in response to Bacillus anthracis infection and muramyl dipeptide. Proc Natl Acad Sci U S A (2008) 3.27
B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature (2010) 3.24
p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet (2007) 3.19
The protein kinase PKR is required for macrophage apoptosis after activation of Toll-like receptor 4. Nature (2004) 3.18
IKKbeta is required for prevention of apoptosis mediated by cell-bound but not by circulating TNFalpha. Immunity (2003) 3.12
Hormone-sensitive lipase deficiency in mice causes diglyceride accumulation in adipose tissue, muscle, and testis. J Biol Chem (2001) 3.10
Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature (2005) 3.09
Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell (2013) 3.08
Chromatin connections to pluripotency and cellular reprogramming. Cell (2011) 3.07
Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance. Proc Natl Acad Sci U S A (2006) 3.02
Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest (2007) 2.99
Essential cytoplasmic translocation of a cytokine receptor-assembled signaling complex. Science (2008) 2.99